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ABSTRACT
Despite the importance of Ras oncogenes as a therapeutic target in human 
cancer, their ‘undruggable’ tertiary structures limit the effectiveness of anti-Ras drugs. 
Canonical Wnt signaling contributes to Ras activity by glycogen synthase kinase 3 (GSK-
3)-dependent phosphorylation at the C-terminus and subsequent degradation. In the 
accompanying report, we show that the anti-helminthic niclosamide directly binds to 
GSK-3 and inhibits Axin functions in colon cancer cells, with reversion of Snail-mediated 
epithelial-mesenchymal transition. In this study, we report that niclosamide effectively 
suppresses Ras and nuclear NFAT activities regardless of the mutational status of Ras at 
nM levels. Mechanistically, niclosamide increased endogenous GSK-3 activity, shortening 
the half-life of mutant Ras. Further, niclosamide activates Raf-1 kinase inhibitory protein, 
a downstream target of Snail repressor. Niclosamide treatment attenuates Ras-induced 
oncogenic potential in vitro and in vivo. These findings provide a clinically available 
repositioned Ras inhibitor as well as a novel strategy for inhibiting the Ras via GSK-3.
INTRODUCTION
Gain-of-function mutations (mostly located at the 
N-terminus) in Ras genes are commonly observed in human 
carcinogenesis as well as in therapeutic resistance [1, 2]. 
The oncogenic mutation of K-Ras is found in 25-30% 
of all cancer screened [3], and its emergence from wild 
type after targeted therapy provides acquired therapeutic 
resistance [4, 5]. While the mutant Ras are a promising 
therapeutic target in human cancer, there are no structurally 
defined surface pockets suitable for drug binding. Recently, 
mutation specific Ras-GTP-Raf binding has emerged for 
therapeutic targeting of Ras [6, 7], although a clinically 
available drug attenuating Ras activity is not yet available.
The oncogenic Ras mutations and genetic alterations 
in other MAPK/ERK signaling pathways, such as BRAF, 
are mutually exclusive events in human cancers, indicating 
that gain-of-Ras activity is essential for tumorigenesis [8]. 
Moreover, reciprocal regulations between the Ras activation 
and canonical Wnt pathways merit special attention. Indeed, 
K-Ras mutation stimulates canonical Wnt activity through 
inhibition of GSK-3 [9]. Similar to Snail and β-catenin in 
the canonical Wnt pathway [10], the Ras harbors a highly 
conserved destruction motif that is phosphorylated by GSK-
3 and subsequently degraded [11]. Raf-1 kinase inhibitory 
protein (RKIP), an endogenous inhibitor of Ras signaling 
pathways, is directly suppressed by Snail, a key inducer 
of epithelial-mesenchymal transition (EMT) [12, 13]. 
Furthermore, transcriptional activity of nuclear factor of 
activated T cells (NFAT) is activated by the Ras/Raf pathway 
and is antagonized by GSK-3 activity [14]. Given the 
important role of GSK-3 in oncogenic signaling including 
in the Snail-mediated EMT program and canonical Wnt 
pathway [10, 15, 16], we hypothesized that modulation of 
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GSK-3 activity by small molecules provides an alternative 
strategy for attenuating oncogenic Ras in human cancer.
Niclosamide is an oral salicylanilide derivative 
that has been FDA-approved since 1960 for use in the 
treatment of various tapeworm infections. Recently, 
niclosamide has emerged in anti-cancer therapeutics for 
various types of cancer [17, 18]. While many studies have 
demonstrated that niclosamide is involved in oncogenic 
signaling pathways such as Wnt, ROS, Notch, mTOR 
and autophage [17–19], its molecular target and mode 
of action is not well-understood. In the accompanying 
report, we show that niclosamide directly targets the Axin-
GSK-3 binding site, resulting in suppression of canonical 
Wnt activity and the Snail-mediated EMT program of 
colon cancer cells. We report that niclosamide increased 
cellular GSK-3 activity and accelerated Ras degradation 
regardless of mutational status. These results provide a 
clinically available drug and a novel strategy for regulating 
oncogenic Ras.
RESULTS AND DISCUSSION
Niclosamide suppresses Ras abundance in a 
GSK-3-dependent manner
The GSK-3 is highly expressed in normal cells and 
is one of the few kinases inactivated following stimulation 
of exogenous growth factors and oncogenic signaling 
[20]. For example, canonical Wnt suppresses GSK-3 
activity through the sequestration of soluble GSK-3 into 
multivesicular endosomes and knockdown of Axin2 
increased nuclear GSK3 activity [21, 22]. Conversely, 
cellular GSK-3 inactivation in the mammary epithelium 
resulted in precancerous condition and development 
of adenocarcinoma [23]. In the accompanying report, 
we show that niclosamide directly targets the Axin-
GSK-3 binding site. To re-validate Axin2-GSK-3-APC 
interaction, we overexpressed His-tagged Axin2 and wild 
type APC in 293 cells and treated niclosamide followed 
by immunoprecipitation analysis. Niclosamide treatment 
decreased GSK-3 interaction, but not APC binding, to Axin2 
(Figure 1A). To directly examine whether niclosamide 
affects endogenous GSK-3 activity, the colon cancer 
cells were subjected to GSK-3 kinase assay following 
niclosamide treatment. Indeed, nM level of niclosamide 
was sufficient to increase endogenous GSK-3 activity in 
colon cancer cells in a dose-dependent manner (Figure 1B), 
indicating that disruption of Axin-GSK3 binding increased 
cellular GSK-3 kinase activity. Similarly to β-catenin and 
Snail, the Ras protein harbors a highly conserved destruction 
motif that is phosphorylated by GSK-3, after which the 
phosphorylated Ras is degraded by β-TrCP-directed 
ubiquitination and proteasomal activity [11]. Importantly, 
the destruction motif of Ras is located on the C-terminus 
while the mutational hot spot in human cancer is on the 
N-terminus [11, 24], providing an alternative approach 
to suppressing mutant Ras by modulation of GSK-3 
(Figure 1C). To prove this hypothesis, we next chose the 
K-Ras-G12V mutant to test the possibility that increased 
GSK-3 activity by niclosamide suppresses mutant Ras. 
We then overexpressed myc-tagged Ras mutant in 293 
cells and treated niclosamide in combination with GSK-3 
specific inhibitor BIO. Indeed, protein abundance of 
mutant K-Ras and endogenous phospho-ERK (extracellular 
signal-regulated kinase) were suppressed by niclosamide, 
while the GSK-3 inhibitor BIO attenuated the effects of 
niclosamide (Figure 1D). To further examine whether 
niclosamide decreases Ras stability, we transfected mutant 
K-Ras expression vector and chased Ras protein abundance 
under cycloheximide treatment. We found that the mutant 
K-Ras protein half-life was significantly shortened by 
niclosamide treatment and the pharmacological effect was 
largely recovered by potent GSK-3 kinase inhibitor BIO 
(Figure 1E). We next chose colon cancer cells having K-Ras 
mutation and treated niclosamide in combination with BIO. 
Indeed, 0.125 μM niclosamide was sufficient to suppress 
the mutant Ras-Erk pathway while BIO re-activated 
the Ras activity in colon cancer cells (Figure 1F). These 
results support that niclosamide decreases Ras stability via 
increasing GSK-3 activity in colon cancer cells.
Niclosamide suppressed RAS activity in colon 
cancer cells regardless of mutational status
Although GSK-3 is a well-known key kinase in the 
canonical Wnt pathway [20, 25], the kinase activity is also 
closely involved in many aspects of the Ras pathway. For 
example, Snail protein stability and abundance are tightly 
controlled by GSK-3-mediated serial phosphorylation 
and subsequent proteasomal degradation [10, 15]. 
Intriguingly, Snail directly suppresses Raf-1 kinase 
inhibitory protein (RKIP), resulting in activation of the 
Raf-1/Mek/Erk pathway and EMT progression [13, 
26, 27]. In addition, nuclear import and transcriptional 
activity of the nuclear factor of activated T-cells (NFAT) 
are activated by Ras/Raf pathway whereas they are 
suppressed by GSK-3 [28–30]. These observations 
suggest that GSK-3 involvement in many layers of Ras/
Raf/Erk signaling. Extending our observations to the 
Ras/Raf/Erk pathway and NFAT transcriptional activity, 
we treated niclosamide on colon cancer cells having 
variable K-Ras status. As shown above, Ras protein 
abundance and ERK phosphorylation were significantly 
decreased by niclosamide treatment regardless of Ras 
mutations (Figure 2A). As a transcriptional target of 
Snail repressor, niclosamide increased RKIP abundance 
in a dose-dependent manner. To further examine 
whether niclosamide suppresses K-Ras-dependent 
NFAT transcriptional activity, we next co-transfected 
NFAT reporter having IL-2 promoter and mutant K-Ras 
in 293 cells in combination with niclosamide. Indeed, 
the reporter activity was increased by overexpression of 
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Figure 1: GSK-3-dependent Ras suppression by niclosamide. (A) The 293 cells were transiently transfected with His-tagged 
Axin2 and wild type APC expression vectors, then treated with increasing doses of niclosamide for an 8h period followed by immunoblot 
analysis of whole cell lysates (lysate). The GSK3 binding activities in lysate were determined by Ni-NTA bead immunoprecipitation (IP) 
followed by immunoblot analysis for endogenous GSK3 and APC. Relative binding of GSK-3 to Axin2 input was determined by ImageJ 
program. (B) The dose-dependent endogenous GSK-3 kinase activity in colon cancer cells was measured. The relative kinase activity 
was determined from triplicated experiments. Data are expressed as means and s.d. The double asterisks denote p < 0.01 by Student’s 
t-tests. (C) Schematic diagram of structural domains of Ras. Conserved phosphorylation residues by GSK-3 are shown in red. (D) The 
293 cells transfected with empty vector or myc-tagged K-Ras G12V mutant expression vector were treated with niclosamide (0.25 μM) 
or in combination with BIO (1 μM) for 18 h. Protein abundance of K-Ras (myc), total Erk 1/2 (Erk), and phospho-Erk 1/2 (pErk) were 
determined by immunoblotting (left panels). The mutant K-Ras abundance was determined with increasing dose of niclosamide (0, 0.125, 
0.25, 05 μM) in combination with BIO (right panels). (E) Mutant K-Ras half-life in control or niclosamide or in combination with BIO 
was determined by pulse-chase analysis and immunoblotting (left panels). The half-life of mutant K-Ras was determined from the slope 
of densitometric protein abundance (right panel). (F) Colon cancer cells having mutant K-Ras were treated with chemicals as indicated for 
18 h, and abundance of Ras, total Erk 1/2 (Erk), and phospho-Erk 1/2 (pErk) were determined by immunoblotting.
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mutant K-Ras, but was largely diminished by niclosamide, 
while non-related NF-ĸB reporter was minimally changed 
(Figure 2B). NFAT is phosphorylated by GSK-3 and 
translocated into the cytosolic space [28]. In colon cancer 
cells, niclosamide effectively decreased nuclear abundance 
along with increased phosphorylation (Figure 2C) and 
transcriptional activity of NFAT1 (also known as NFATp) 
in a dose-dependent manner (Figure 2D). These results 
support that niclosamide efficiently suppresses the Ras/
Raf/Erk pathway and the Ras-responsible transcriptional 
program.
Niclosamide inhibits Ras-induced 
transformation
To examine the functional relevance of niclosamide 
on Ras suppression, we transiently transfected mutant 
K-Ras and assayed anchorage-independent growth. 
Overexpression of mutant K-Ras gave rise to significantly 
higher numbers of larger colonies in soft agar than control 
vector transfectants, and niclosamide treatment suppressed 
anchorage-independent growth in a dose-dependent 
manner (Figure 3A). In the accompanying report, we 
show that niclosamide significantly suppressed the 
in vivo tumorigenic potential of colon cancer cells having 
mutations of APC (SW480) or β-catenin (HCT116) with 
K-Ras. To examine the functional roles of niclosamide 
on Ras oncogene, we next transiently transfected mutant 
K-Ras into 293 cells and assessed in vivo tumorigenic 
potential with niclosamide. Indeed, tumor initiating 
potential induced by mutant K-Ras was attenuated by 
administration of niclosamide (Figure 3B). These results 
support that niclosamide efficiently suppresses Ras 
activity in vitro and in vivo.
Figure 2: Niclosamide suppresses Ras activity at various levels. (A) Colon cancer cells having mutant or wild type K-Ras 
treated with nM niclosamide for 18 h, and abundance of Ras, total Erk 1/2 (Erk), phospho-Erk 1/2 (pErk), and PKIP were determined by 
immunoblotting. Mutational status of K-Ras is noted on cell lines. (B) NFAT reporter activities in 293 cells were determined in K-Ras 
G12V transfected with a control (-) or increasing concentration of niclosamide. Non-related NF-ĸB reporter serves as negative control. 
(C) Nuclear abundance and phosphorylation of NFAT1 in colon cancer cells. HCT116 and SW480 cells were treated with increasing doses 
of niclosamide and NFAT1 abundance was measured with immunoblot analysis from nuclear fraction. Hyperphosphorylated and active 
dephosphorylated isoforms denote black and red arrows, respectively. HDAC1 serves as loading control for nuclear fraction. (D) NFAT 
reporter activities in colon cancer cells were determined with control or various concentration of niclosamide. The reporter activity in (B) 
and (D) was normalized to the co-transfected pRL-SV40-renilla activity from triplicate experiments. Data are expressed as means and s.d. 
The double asterisks denote p < 0.01; one asterisk denotes p < 0.05.
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Together with activation of the canonical Wnt 
pathway, somatic mutations of small GTPase Ras 
isoforms are frequently found in human cancer, these 
genetic alterations being associated with resistance 
against standard or targeted therapeutics [4, 5]. Despite its 
importance as an anticancer target, Ras protein is hardly 
Figure 3: Niclosamide inhibits Ras-induced cell transformation. (A) Representative colonies of soft agar assays as described in 
Methods (left panels). The data represent the colony formation ability of K-Ras transfected 293 cells treated with different concentrations 
of niclosamide. The colony number was counted from 5 separate fields (right panel). Results are shown as means and s.d. Two asterisks, 
P < 0.01. (B) Niclosamide inhibits the K-Ras-induced tumorigenic potential of 293 cells in vivo. The 293 cells were transiently transfected 
with vector or mutant K-Ras, and a suboptimal number of cells (5 x 105) cells were inoculated into the flank of athymic nude mice prior to 
24 h of niclosamide treatment. Vehicle or niclosamide in vehicle (50 mg/kg, 200 mg/kg) was intraperioneally administered. Two asterisks, 
P < 0.01 by Fisher’s exact test.
Figure 4: A schematic diagram depicting a potential mechanism by which niclosamide suppresses Ras activity in 
cancer cells.
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targetable by small molecules owing to the absence of 
druggable pockets on its surface. In this study, we provide 
evidence that increased GSK-3 activity by repositioned 
niclosamide efficiently suppresses Ras activity regardless 
of its mutational status via increased GSK-3 activity in 
colon cancer cells (Figure 4). Our observations suggest an 
alternative strategy as well as a clinically available drug 
for regulation of Ras in human cancer.
MATERIALS AND METHODS
Cell lines and reagents
Colon cancer cell lines (HCT116, SW480 and 
DLD1) and 293 cells were from ATCC and were 
maintained under conditions recommended by the 
provider. All cell lines were verified using DNA 
fingerprinting analysis with short tandem repeat markers. 
The niclosamide was purchased from Cayman, GSK-3 
specific inhibitor BIO (6-bromoindirubin-3′-oxime, 
B1686) was purchased for Sigma, and chemicals were 
solubilized in DMSO for in vitro experiments. K-Ras 
G12V mutant was kindly provided by Dr. K. H. Chun 
and its sequence was verified for experiments. NFAT 
reporter having IL-2 promoter was obtained from Addgene 
(plasmid #10959) and NF-ĸB reporter as a negative control 
was purchased from Agilent Technologies (219078). 
Expression vector for wild type APC was obtained from 
Addgene (#16507).
GSK-3 kinase assay, reporter assay, immunoblot 
assay, immunoprecipitation, and pulse chase 
experiment
GSK-3 kinase activity in whole cells was performed 
using the GSK-3 kinase assay kit (ENZO Biochem) as 
described previously [16]. For reporter assay, cells were 
transfected with 100 ng of reporter gene constructs with 
1 ng of pRL-SV40-Renilla vector. Reporter activities were 
measured with a dual luciferase assay system (Promega) 
48 h after transfection and normalized by measuring co-
transfected renilla activity. Reporter gene activities are 
presented as relative light units to those obtained from 
negative DMSO control. For the western blot analyses, 
protein extracts were prepared in Triton X-100 lysis 
buffer. Antibodies against pan Ras (sc16691, Santa Cruz, 
1:2,000), Erk1/2 (4695S, Cell Signaling, 1:1,000), pErk1/2 
(4377S, Cell Signaling, 1:1,000), RKIP (sc376925, Santa 
Cruz, 1:1,000), NFAT-p (sc7296, Santa Cruz, 1:500), myc 
(LF-MA0046, Ab Frontier, 1: 5,000) and Tubulin (LF-
PA0146A, Ab Frontier, 1:5,000) were obtained from the 
commercial vendors. For immunoprecipitation assay, His-
tagged Axin2 expression vector and wild type APC were 
transiently transfected into 293 cells. After a 48 h period, 
the cells were treated with different dose of niclosamide 
for 8 h, and whole cell Triton X-100 lysates were 
incubated with Ni-NTA beads (Invitrogen). The recovered 
proteins were resolved by SDS-PAGE and subjected to 
immunoblot analysis for GSK3, APC, and input (1/20 
volume) control. The pulse-chase analyses of K-Ras 
mutant were performed as described previously [15]. In 
brief, 293 cells were transfected with myc-tagged K-Ras 
G12V expression vector for 48 h. The transfected cells 
were treated with cycloheximide (50 μg/ml), followed 
by chase for the indicated time periods in the presence 
or absence of niclosamide (0.25 μM) and BIO (1 μM). 
Cell lysates were harvested and subjected to immunoblot 
analysis against myc-tag. The band intensity was measured 
with densitometer, and relative intensity compared to 
loading control was calculated with ImageJ program 
provided by NIH. The nuclear abundance of NFAT was 
determined from nuclear-cytosolic fractionation with 
hypotonic buffer solution. Briefly, the colon cancer cells 
(1 x 106) were collected into microcentrifuge tubes. The 
PBS-washed cells were treated with 400 μl of hypotonic 
buffer (10 mM HEPES, pH7.9; 10 mM KCl; 1 mM 
DTT with protease inhibitors) on ice for 5 min. The cell 
membrane was ruptured by adding 10% NP-40 to a final 
concentration of 0.6%, then vigorously vortexed for 
10 sec followed by high-speed centrifuge for 30 sec. The 
supernatant cytosolic fractions were collected separately, 
and nuclear pellets were washed with ice-cold PBS twice. 
Nuclear protein was extracted with hypertonic buffer 
(20 mM HEPES, pH7.9; 0.4 M NaCl; 1mM DTT with 
protease inhibitors) for 15 min on ice followed by high-
speed centrifuge.
Soft agar assay
293 cells transiently transfected with empty vector 
or K-Ras G12V mutant were suspended at 1 x 104 cells 
per 6-well plate with 1 ml of 0.3% low-melting agar in 
2X DMEM containing 20% FBS and overlaid on a layer 
of 1 ml of 1% agar in the same medium. Two weeks 
later, colonies were visualized by staining with 0.05% 
crystal violet in 10% ethanol for 30 min and viable 
colonies that contained > 50 cells were counted from 
5 fields with a stereomicroscope. Representative colonies 
were photographed and 2 independent experiments 
were performed.
Animal experiment
All animal experiments were performed in 
accordance with the Institutional Animal Care and Use 
Committee of Yonsei University and approved by the 
Animal Care Committee of the Yonsei University College 
of Dentistry. Female athymic nude mice (6 weeks old) were 
used for xenograft assays. The 293 cells were transiently 
transfected with vector control or mutant K-Ras G12V 
prior to 48 h of in vivo inoculation. A suboptimal number of 
the cells (5 x 105) were resuspended in 100 μl of PBS and 
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injected into flank subcutaneous tissue. For intraperitoneally 
administration, vehicle (10% Cremophor EL and 0.9% 
NaCl) or niclosamide in vehicle (50 mg/kg, 200 mg/kg) 
were injected daily (6 days/week), and the mice were 
monitored daily and weighed twice weekly for 6 weeks.
Statistics
All statistical analysis of in vitro study was 
performed with two-tailed Student’s t-tests; data are 
expressed as means and s.d. The double asterisks denote 
P < 0.01; one asterisk denotes P < 0.05. No statistical 
method was used to predetermine sample size.
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